Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anthony Faugno

Pulmonary Disease Boston, MA Medical Doctor

NPI 1992067698 CMS profile 790068

800 Washington St, Boston, MA 02111

Open in the dashboard

General payments

$131,900

9 records reported · program years 2021–2025

Research payments

$703,000

Paid to them · 11 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Faugno of Boston, MA is reported in the CMS Open Payments database as having received $131,900 across 9 general payments and $703,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36 1
2023 General $131,769 7
2022 General $95 1
2022 Research $675,000 10
2021 Research $28,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Faugno
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Anthony Faugno were reported at $36. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Anthony Faugno Pulmonary Disease median Middle half National median
2019 $0 $377 $109–$1,340 $163
2020 $0 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $95 $390 $100–$1,457 $149
2023 $131,769 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $36 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Moderna TX, Inc. $131,750 6 payments
  2. Alnylam Pharmaceuticals Inc. $114 2 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $36 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $131,750 6 payments
  2. Travel and Lodging $95 1 payment
  3. Food and Beverage $55 2 payments
Products named General payments · program years 2021–2025
  1. Moderna Covid-19 Vaccine $131,750 6 payments
  2. LifeVest $36 1 payment
  3. ONPATTRO $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Moderna TX, Inc. $703,000 11 payments

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$36,062

Medicare's payments for the services billed

Medicare patients

115

Average age 72

Services billed

356

60 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 60%
Ischemic heart disease 58%
Chronic kidney disease 52%
COPD 50%
Diabetes 47%
Arthritis 47%
Atrial fibrillation 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record